Open Access

Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels

  • Authors:
    • Jian Hui Xu
    • Xing Zhen Liu
    • Wei Pan
    • Da Jin Zou
  • View Affiliations

  • Published online on: March 14, 2017
  • Pages: 2765-2787
  • Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Systemic inflammation, which can be induced by metabolic endotoxemia, and corresponding high‑fat diet‑mediated metabolic disorders are associated with gut microbiota. In the present study reverse transcription-polymerase chain reaction, immunofluorescence, pyrosequencing, ELISA and Oil Red O staining were performed to assess whether berberine can protect against diet-induced obesity, through modulating the gut microbiota and consequently improving metabolic endotoxemia and gastrointestinal hormone levels. Alterations in the gut microbiota induced by berberine resulted in a significant reduction in bacterial lipopolysaccharide levels in portal plasma. Levels of inflammatory and oxidative stress markers, as well as the mRNA expression levels of macrophage infiltration markers in visceral adipose tissue, were also reduced by berberine. Inhibition of the inflammatory response was associated with a reduction in intestinal permeability and an increase in the expression of tight junction proteins. In addition, berberine was reported to restore aberrant levels of gut hormones in the portal plasma, such as glucagon‑like peptide‑1 and ‑2, peptide YY, glucose‑dependent insulinotropic polypeptide and pancreatic polypeptide. The present findings indicated that berberine, through modulating gut microbiota, restored the gut barrier, reduced metabolic endotoxemia and systemic inflammation, and improved gut peptide levels in high‑fat diet‑fed rats. The present study suggests that berberine may be an effective therapeutic strategy for the treatment of obesity and insulin resistance.


Berberine, which is an alkaloid extracted from Rhizoma coptidis, has been traditionally used in Chinese medicine to treat gastrointestinal infections, due to its antimicrobial properties. Previous clinical research and animal studies have demonstrated that berberine can regulate glucose and lipid metabolism, and attenuate insulin resistance (13). Several mechanisms have been proposed to explain the actions of berberine in in vitro and in vivo models; these include: The activation of AMP-activated protein kinase to downregulate the expression of lipogenesis genes and upregulate the expression of energy expenditure genes (4); the inhibition of intestinal disaccharidases and α-glucosidase (5,6); the upregulation of the hepatic low-density lipoprotein receptor (7); the inhibition of intestinal cholesterol absorption (8); and increased intestinal glucagon-like peptide-1 (GLP-1) secretion (9,10). Since berberine has been reported to have poor intestinal absorption and very low absolute bioavailability, with values ranging between 0.36 and 0.68% in rats, it may be hypothesized that berberine exerts its effects in the intestinal tract prior to its absorption (11,12).

Accumulating evidence suggests that the gut microbiome serves an important role in obesity and related metabolic abnormalities. Taking into consideration the antibacterial activity of berberine, modulation of the gut microbiota has been suggested as another possible mechanism for its actions. Xie et al (2) reported that berberine significantly increased the intestinal expression of fasting-induced adipose factor (Fiaf), which acts as a lipoprotein lipase inhibitor, thereby inhibiting triglyceride deposition in adipocytes. Furthermore, it has been reported that Lactobacillus paracasei may upregulate Fiaf expression in colonic epithelial cells (13). These findings indicate that, through modulating the gut microbiota, berberine may increase the expression of Fiaf.

The leakage of bacterial-derived lipopolysaccharide (LPS) through the damaged intestinal mucosa into the circulation is a well-established mechanism of metabolic endotoxemia that can trigger systemic inflammation. Zhang et al (14) previously reported that berberine may prevent obesity and insulin resistance in high-fat diet (HFD)-fed rats by modulating the gut microbiota, thus contributing to the alleviaton of inflammation via a reduction in serum LPS-binding protein and monocyte chemotactic protein-1 (MCP-1). However, there is currently little information available on whether berberine can modulate endotoxemia and intestinal or systemic inflammation.

Previous studies have suggested that gut microbiota may contribute to the development of obesity and related disorders by modulating the synthesis of enteroendocrine peptides involved in glucose and energy homeostasis. A series of studies by Cani et al (1518) reported that prebiotic use can interfere with plasma levels of intestinal peptides, causing an increase in GLP-1, GLP-2 and peptide YY (PYY), and a decrease in gastric inhibitory polypeptide (GIP) in rodent and human subjects. Short-chain fatty acids (SCFAs), produced during the bacterial fermentation of non-digestible carbohydrates, have been shown to promote GLP-1 and PYY secretion by stimulating the expression of G protein-coupled receptor 41 and 43 in enteroendocrine cells (L-cells) (1922). Furthermore, prebiotics have been reported to promote GLP-2 production by increasing the number of intestinal L-cells and the mRNA expression of proglucagon (15). Taken together, these studies suggest that the fermentation of prebiotics by intestinal bacteria can interfere with gut peptide production. In addition, previous studies have revealed that berberine can increase the number of intestinal L-cells and thereby increase plasma GLP-1 levels in normal and diabetic rats (9,10,23). Furthermore, berberine has been demonstrated to promote ileal GLP-2 secretion and thus decrease LPS plasma levels in diabetic rats (24). Since GLP-2 is known to regulate the proliferation of intestinal epithelial cells and thus the integrity of the gut barrier, berberine may also promote intestinal integrity through modulating GLP-2 levels. Although previous studies have suggested that the effects of berberine on glucose metabolism and energy homeostasis are related to its modulatory effects on gut hormones, it remains to be elucidated whether other hormones may also be involved.

In order to investigate the effects of berberine administration on the gut and the gut microbiome, the present study employed a rat model of diet-induced obesity. Alterations in gut microbiota were assessed using 454 pyrosequencing, whereas intestinal hormone levels were assessed using Luminex technology. Intestinal permeability, the expression of tight junction proteins, endotoxemia, and systemic inflammation were also investigated.

Materials and methods


Berberine and fluorescein isothiocyanate (FITC)-dextran were purchased from Merck KGaA (Darmstadt, Germany). All diets were purchased from Research Diets, Inc. (New Brunswick, NJ, USA). Rat metabolic hormone kit, GLP-1 (cat. no. EGLP-35K) and GLP-2 (cat. no. EZGLP2-37K) ELISA kits were purchased from Merck KGaA. TRIzol® reagent and DAPI were purchased from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Reverse transcription kit and SYBR-Green were purchased from Takara Biotechnology Co., Ltd. (Dalian, China). Optimal cutting temperature (OCT) compound was purchased from Sakura Finetek USA, Inc. (Torrance, CA, USA). Claudin1 (cat. no. ab203563), claudin2 (cat. no. ab53032) and GLP-1 antibodies (cat. no. ab22625) were purchased from Abcam (Cambridge, MA, USA). Goat anti-rabbit Cy3-conjugated secondary antibody (cat. no. 111-165-003) was purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA). QIAamp DNA stool minikit was purchased from Qiagen, Inc. (Valencia, CA, USA). FastPfu polymerase was purchased from TransGen Biotech Co., Ltd. (Beijing, China). Axy-Prep DNA Gel Extraction kit was purchased from Axygen Biotechnology Co., Ltd. (Taizhou, China).


Thirty male Sprague-Dawley rats (age, 6 to 8 weeks; weight, ~260 g) were purchased from the SLAC Laboratory Animal Co., Ltd. (Shanghai, China), and were housed in a controlled environment (21 to 25°C; inverted 12-h daylight cycle; lights-off at 6:00 p.m.) in groups of 2 rats/cage and given free access to water and food. Following an acclimation period of 1 week, the rats were fed a control diet (Ctl group; n=10, 10% kcal from fat) or a HFD (HF group; n=20, 45% kcal from fat) for 14 weeks. Following 14 weeks, 10 rats from the HF group were maintained on the HFD however, they were given an oral supplement of berberine (150 mg/kg/day) for 6 weeks (HB group). For the duration of the study, the animals were weighed once a week, and their food intake was measured twice a week. All experimental procedures were validated by the Ethics Committee of Changhai Hospital, The Second Military Medical University (Shanghai, China).

Oral glucose tolerance test

The glucose tolerance tests were conducted following 6 weeks of berberine administration. Following a 12 h fast, the rats received an oral load of 50% glucose solution (2.0 g/kg). Blood glucose was sampled in the tail vein before and 15, 30, 60, 90 and 120 min following glucose administration with an ACCU-CHEK glucose meter (Roche Diagnostics, Basel, Switzerland).

In vivo intestinal permeability

Rats from all groups were fasted for 6 h and were subsequently administered FITC-dextran diluted in saline by gavage (500 mg/kg, 125 mg/ml). Following 1 and 4 h, 500 µl of blood was sampled from the tail vein, placed in ice-cold heparinized tubes and centrifuged (12,000 × g for 3 min at 4°C). The obtained plasma was then diluted with PBS (1:3 v/v) and the FITC-dextran concentration was determined using a fluorescence spectrophotometer (F7000; Hitachi, Ltd., Tokyo, Japan) at an excitation wavelength of 485 nm and an emission wavelength of 535 nm. A standard curve was obtained by diluting serial concentrations of FITC-dextran in non-treated plasma diluted with PBS (1:3 v/v).

Blood samples

At the end of the experiments, the rats were anesthetized by an intraperitoneal injection of 30 mg/kg pentobarbital following a 12-h fasting period. Blood samples were collected from the orbital plexus and the hepatic portal vein and centrifuged (2,000 × g for 10 min at 4°C) to obtain plasma for further biochemical analyses. LPS concentration in portal plasma was determined using a kit utilizing Tachypleus amebocyte lysate (Endosafe; Charles River Laboratories International, Inc., Wilmington, MA, USA) and estimated using the kinetic turbidimetric method. Intestinal hormone levels in portal plasma [total GIP, total pancreatic polypeptide (PP) and PYY] were determined in triplicate using a rat metabolic hormone kit (cat. no. RMHMAG-84K; Merck KGaA) and Luminex technology (Bio-Plex Multiplex system; Bio-Rad Laboratories, Inc., Hercules, CA, USA) according to the manufacturer's protocol. Total portal GLP-1 and GLP-2 levels were determined using ELISA kits. Plasma alanine triglycerides, cholesterol aminotransferase (ALT) and aspartate aminotransferase (AST) were determined using an automatic biochemistry analyser (HITACHI 2000; Hitachi, Ltd.).

Tissue samples

The rats were anesthetized using chloral hydrate (400 mg/kg) and sacrificed by cervical dislocation. The visceral adipose tissue, and segments of the liver and proximal colon, were then removed. Tissues were immediately immersed in liquid nitrogen and stored at −80°C for further mRNA analysis. The remaining liver samples were used for hepatic lipid analysis and were stained with Oil Red O to detect fat droplets. The proximal colon samples were used for further immunofluorescence analysis.

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted form tissue samples using TRIzol® reagent according to the manufacturer's protocol. Total RNA (1 µg) was reverse transcribed into cDNA using the PrimeScript RT reagents kit (Takara Biotechnology Co., Ltd.). Briefly, the sample was incubated at 37°C for 15 min and then at 85°C for 5 sec. The mRNA levels of the different genes were examined using RT-qPCR. qPCR was conducted using the Rotor-Gene 3000 system and software (Qiagen, Inc., Valencia, CA, USA) using SYBR-Green. The thermocycling conditions were as follows: 95°C for 2 min, followed by 40 cycles of 95°C for 10 sec, 55°C for 30 sec and 72°C for 30 sec. The primer sequences for the targeted genes are presented in Table I. The relative expression of each gene was normalized to the expression of the GAPDH gene and was calculated using the comparative Cq method (ΔΔCq) (25).

Table I.

Primer sequences used for reverse transcription-quantitative polymerase chain reaction.

Table I.

Primer sequences used for reverse transcription-quantitative polymerase chain reaction.

GeneForward primers (5′→3′)Reverse primers (5′→3′)

[i] TNF, tumor necrosis factor; IL, interleukin; PAI-1, plasminogen activator inhibitor-1; NADPHox, nicotinamide-adenine dinucleotide phosphate oxidase; STAMP-2, six transmembrane protein of prostate-2; MCP-1, monocyte chemotactic protein-1; F4/80, EGF-like module-containing mucin-like hormone receptor-like 1; ZO-1, zonula occludens-1.

Oil Red O staining

Hepatic fat accumulation was evaluated by Oil Red O staining. Liver tissue was embedded in OCT compound and frozen in liquid nitrogen. The tissue was sliced into 8-µm cryostat sections and stained with 0.05% Oil Red O at room temperature for 30 min to detect lipid droplets. Photomicrographs were taken with a Nikon Eclipse E600 microscope (Nikon Corporation, Tokyo, Japan). The percentage of positively stained Oil Red O areas was quantified using the Image-Pro Plus software (version 6; Media Cybernetics, Inc., Rockville, MD, USA).


Segments of the proximal colon were removed, washed with PBS and fixed immediately in 4% paraformaldehyde. The fixed tissue was dehydrated in ethanol, cleared in xylene, and embedded in paraffin. The paraffin sections (4-µm) were deparaffinized, rehydrated, treated with EDTA antigen retrieval buffers for 25 min at 4°C, and incubated with 5% bovine serum albumin (Sangon Biotech Co., Ltd., Shanghai, China) for 20 min to block non-specific binding. The slides were incubated with rabbit anti-claudin-1 (dilution, 1:300) or rabbit anti-claudin-2 primary antibodies (dilution, 1:300) overnight at 4°C in a moist chamber. The number of L-cells was determined by staining with rabbit anti-GLP-1 primary antibody (dilution, 1:300) overnight at 4°C. Subsequently, slides were washed 3 times with PBS and incubated with goat anti-rabbit Cy3-conjugated secondary antibody (dilution, 1:100) for 50 min at room temperature. The slides were washed a further 3 times with PBS, mounted with ProLong Gold antifade reagent with DAPI, and analyzed under a Nikon Eclipse TE-2000-U fluorescent microscope (Nikon Corporation). A total of 5 fields from each intestinal segment were selected, and the mucosal area was manually delineated and measured by an image analyzer (Motic Image Plus 2.0ML; Motic Incorporation, Ltd., Causeway Bay, Hong Kong) for determining the number of L-cells. All stained samples were analyzed in a double-blind manner by 2 experienced investigators.

DNA extraction from fecal samples

Cecal feces were collected from the caecum of each rat whilst under abdominal anaesthesia (30 mg/kg sodium pentobarbital) and were stored at −80°C prior to analysis. The total bacterial genomic DNA was extracted from the frozen feces (200 mg) using the QIAamp DNA stool minikit according to the manufacturer's protocol.

PCR amplification of 16S rRNA and pyrosequencing

The extracted DNA served as a template to amplify the V1-3 region of the 16S rRNA gene. The primers used were as follows: Forward primer 5′-NNNNNNNNAGAGTTTGATCCTGGCTCAG-3′ and reverse primer 5′-NNNNNNNNTTACCGCGGCTGCTGGCAC-3′. NNNNNNNN indicates the 8-base bar code sequence used to tag each PCR product, and the underlined sequence indicates the broad-range primers used to amplify the V1-3 region of the 16S rRNA gene. The PCR amplification mixture (20 µl) contained 10 ng template DNA, 4 µl 5X PCR FastPfu buffer, 0.2 units FastPfu polymerase, 2.5 mM dNTP mixture and 0.4 µM of each primer. The PCR reactions were performed using a GeneAmp PCR system 9700 cycler (Applied Biosystems; Thermo Fisher Scientific, Inc.). The PCR conditions were as follows: Denaturation at 95°C for 2 min, followed by 25 cycles at 95°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec, and a final extension at 72°C for 5 min. The PCR products were separated by electrophoresis and subsequently cut from the 2% agarose gel. The products were purified using the Axy-Prep DNA Gel Extraction kit. The purified DNA was quantified using the QuantiFluor system (Promega Corporation, Madison, WI, USA). A total of 4 µg purified DNA was added to a master pool, and the DNA pool was sent to Major Biosystem Co., Ltd., (Taipei, Taiwan) for pyrosequencing using the GS FLX system (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's protocol. The company analysed the data using Weighted UniFrac principal coordinates analysis (PCoA), principal component analysis (PCA), redundancy analysis (RDA), Monte Carlo permutation and Mothur tests.

Statistical analysis

Experiments were repeated at least 3 times and data are expressed as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference. The statistical significance of the difference between groups was assessed by one-way analysis of variance, followed by a post hoc Bonferroni's multiple comparison tests; or by Kruskal-Wallis test for non-parametric data, followed by a Dunn's multiple comparison test. Correlations between parameters were assessed by the Spearman's correlation coefficent. The analysis was performed using SPSS software version 16.0 (SPSS, Inc., Chicago, IL, USA) and figures were created using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA).


Berberine prevents obesity and improves glucose homeostasis in HFD-fed rats

Rats maintained on a HFD for 14 weeks exhibited a significant increase in body weight compared with the control rats (636.26±44.83 vs. 591.34±30.65 g; P<0.01; Fig. 1A). Treatment with berberine for 6 weeks significantly reversed the body weight increase of HFD-fed rats compared with untreated HFD-fed rats (658.58±54.04 vs. 715.59±46.70 g; P<0.05; Fig. 1A). As a result, rats in the HB treatment group had a body weight similar to the control group (Fig. 1A). During the course of the study, food intake was monitored twice a week. Average daily food intake appeared to be smaller in the HB treatment group; however, no significant difference was revealed when compared with the HF group (Fig. 1B). These results suggested that berberine may prevent obesity without interfering with food intake.

Fasting blood glucose and fasting blood insulin appeared to be significantly increased in rats of the HF group compared with the control group (Fig. 1C and D). The HFD also caused impaired glucose tolerance and insulin resistance, which was apparent by the significantly increased homeostatic model assessment of insulin resistance index and the significantly increased area under the curve following glucose challenge (Fig. 1E and F). Berberine treatment significantly improved fasting blood insulin and insulin resistance, however, not fasting blood glucose (Fig. 1C-F).

Berberine alleviates HFD-induced hepatic steatosis and injury

Hepatic steatosis was evaluated by measuring hepatic triglyceride contents via Oil Red O staining, whereas hepatic injury was evaluated by measuring circulating liver enzyme levels. Rats maintained on a HFD developed hepatic steatosis and injury, as reflected by the significantly increased hepatic triglyceride contents and ALT levels (Fig. 2A-D). Furthermore, Oil Red O staining demonstrated that large lipid droplets accumulated in the liver of HFD-fed rats (Fig. 2E). Berberine supplementation significantly decreased plasma ALT levels however, it did not affect aspartate aminotransferase levels when compared with untreated HFD-fed rats (Fig. 2C and D). A marked decrease in the amount of Oil Red O-stained lipid droplets in the berberine-treated group was also observed (Fig. 2E). These results suggested that HFD-induced hepatic steatosis and injury may be significantly alleviated by berberine.

Berberine reduces endotoxemia and visceral adipose tissue inflammation in HFD-fed rats

LPS levels in portal plasma were significantly higher in HFD-fed rats compared with control rats (Fig. 3A). Following treatment with berberine for 6 weeks, LPS plasma levels in HFD-fed rats were significantly reduced when compared with the untreated HFD-fed rats; however, LPS levels in berberine-treated rats remained higher than in control rats. With regards to inflammation and oxidative stress in visceral adipose tissue, and their role in obesity and insulin resistance, the following seven genes were investigated: Tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), plasminogen activator inhibitor-1 (PAI-1), six transmembrane protein of prostate-2 (STAMP-2), nicotinamide-adenine dinucleotide phosphate oxidase (NADPHox), MCP-1 and EGF-like module-containing mucin-like hormone receptor-like 1 (F4/80). In visceral adipose tissue samples, the mRNA expression levels of these genes were significantly increased in HFD-fed rats compared with in control rats (Fig. 3B-H). Treatment with berberine significantly reduced IL-1β, PAI-1, STAMP-2, NADPHox, MCP-1 and F4/80 mRNA expression levels compared with in untreated HFD-fed rats (Fig. 3C-H). Berberine appeared to have no effect on TNF-α mRNA levels compared with in untreated HFD-fed rats (Fig. 3B).

To explore whether endotoxemia affected inflammatory processes in visceral adipose tissue, the correlation between LPS plasma levels and TNF-α, IL-1β, PAI-1, STAMP-2, NADPHox, MCP-1 and F4/80 mRNA expression levels was investigated. The present results indicated that LPS portal plasma levels were positively correlated with the mRNA expression levels of TNFα, IL-1β, PAI-1, NADPHox, STAMP2, MCP-1 and F4/80 in visceral adipose tissue (Fig. 4A-G). These multiple correlations suggested that gut microbiota and endotoxemia may synergistically contribute to inflammation, oxidative stress and macrophage infiltration in HFD-fed rats.

Berberine reduces intestinal permeability and ameliorates the expression and distribution of tight junction proteins in HFD-fed rats

To investigate whether endotoxemia could exert an effect on intestinal permeability, the plasma concentration of FITC-dextran was examined. In accordance with the changes in plasma LPS levels, a marked increase in plasma FITC-dextran area under the curve was observed in HFD-fed rats compared with in the control rats (Fig. 5A). Treatment with berberine significantly reduced plasma FITC-dextran concentration in the HFD-fed rats compared with in untreated rats (Fig. 5A and B). Furthermore, portal plasma LPS levels appeared to be positively correlated with plasma FITC-dextran concentration (Fig. 5C). These findings suggested that berberine may reduce HFD-induced endotoxemia, through interfering with the control of intestinal permeability.

Tight junction proteins control paracellular permeability. In the present study, the effect of berberine on the expression and distribution of candidate tight junction proteins, including claudin-1, claudin-2, zonula occludens-1 (ZO-1) and occludin, was investigated using RT-qPCR and immunofluorescence. Claudin-1, claudin-2, ZO-1 and occludin mRNA expression levels in the proximal colon segments from HFD-fed rats were significantly decreased, as compared with rats in the control group. Treatment with berberine appeared to restore claudin-1 and ZO-1 mRNA expression levels, however, it had no significant effect on claudin-2 and occludin mRNA expression levels (Fig. 6A-D).

As shown in Fig. 7, immunofluorescence revealed that the tight junction proteins claudin-1 and claudin-2 are normally distributed along the epithelial sheet from the crypt to the villous, and the staining for both proteins appeared continuous and dense. Conversely, in HFD-fed rats, the staining revealed a translocation of claudin-1 and claudin-2 from the tight junction to the luminal side of the crypt. Tissue from berberine-treated rats exhibited strong claudin-1 and claudin-2 staining in the villous surface, similar to the control group (Fig. 7A and C). These observations suggested that berberine treatment may attenuate the HFD-induced redistribution of claudin-1 and claudin-2. Furthermore, in accordance with the mRNA analysis results, the immunohistochemical staining scores (quantified by v.6 Image-Pro Plus software) for claudin-1 protein appeared significantly higher in berberine-treated rats compared with in untreated HFD-fed rats (Fig. 7B and D).

Berberine modulates intestinal hormone levels in portal plasma

Levels of the intestinal hormones GLP-1, GLP-2, PP and PYY appeared to be significantly reduced, whereas GIP levels were significantly increased in portal plasma samples of HFD-fed rats. Treatment with berberine restored the concentrations of GLP-1, GLP-2, PYY and GIP to those of the control rats (Fig. 8A-C). Furthermore, berberine almost doubled the portal plasma GLP-1 and GLP-2 levels as compared with HFD-fed rats. Berberine supplementation increased PP plasma levels significantly (Fig. 8C). In addition, berberine-treated rats exhibited a 3-fold increase in proglucagon mRNA expression levels and in the number of GLP-1-positive L-cells in the proximal colon compared with HFD-fed untreated rats (Fig. 8D and E).

Berberine alters the composition of the gut microbiome

In order to investigate the effects of a HFD and berberine intake on the composition of the gut microbiome, 454 pyrosequencing of the bacterial 16S rRNA gene V1-V3 region was performed. A total of 602,852 usable reads (119,071 unique sequences) obtained from 20 samples were delineated into 10,385 operational taxonomic units (OTUs) at the 97% similarity level. Rarefaction curves indicated that most of the diversity of each microbial group was successfully sampled (Fig. 9A). Berberine supplementation appeared to cause a significant reduction in the richness of the gut microbiota, as compared with HFD-fed untreated rats, which was confirmed by Ace and Chao estimators (Table II). Berberine treatment also appeared to significantly reduce the diversity of the gut microbiota, which was confirmed by the Shannon and Simpson indices (Table II).

Table II.

Community richness and diversity estimator.

Table II.

Community richness and diversity estimator.

Sample IDaReadsbOTU numbersAceChaoCoverageShannonSimpson
HB group
HF group
Ctl group

a Sample names.

b Trimmed sequence numbers assigned to OTUs. OTU, operational taxonomic unit; HB, high fat diet supplemented with berberine for 6 weeks; HF, high fat diet; Ctl, normal diet.

A total of 10,119 OTUs (contributing to 98.8% of all sequencing reads) were assigned to 19 phyla by Mothur analysis. The most abundant phyla included Firmicutes (7,432 OTUs, 70.3% of all reads), Bacteroidetes (1,044 OTUs, 10.4% of all reads), Fusobacteria (457 OTUs, 8.2% of all reads), Proteobacteria (509 OTUs, 6.1% of all reads) and Actinobacteria (348 OTUs, 3.0% of all reads). As revealed by taxon-based analysis, there was a significant decrease in the abundance of the Actinobacteria phylum in the HFD-fed group compared with in the control group, whereas no significant differences were observed in the Firmicutes, Bacteroidetes, Fusobacteria and Proteobacteria phyla (Table III). Berberine markedly altered the gut microbiota composition at the phylum level, significantly increasing the abundance of Fusobacteria and Proteobacteria, and decreasing the abundance of Firmicutes and Actinobacteria (Table III). Berberine had no effect on the abundance of the Bacteroidetes phylum. In addition, berberine appeared to significantly affect the abundance of 59 genera (Table III). Among these, 12 genera displayed a 10-fold increase, and 37 genera displayed a 10-fold decrease in average frequency, compared with the HFD group rats. Furthermore, 37 genera were identified exclusively in berberine-treated rats, whereas 18 genera were identified exclusively in HFD-fed untreated animals.

Table III.

Differentially abundant features analysis at the phylum or genus level.

Table III.

Differentially abundant features analysis at the phylum or genus level.


Phylum/GenusHB (%) mean ± SDHF (%) mean ± SDCtl (%) mean ± SDHB vs. HFHF vs. CtlHB vs. Ctl
  Acidobacteria 0.00135±0.000660.00293±0.0008 0.00199±0.000950.438700.717050.68879
  Actinobacteria 0.02004±0.00564 1.94705±0.72971 7.24482±2.453390.014080.045070.00631
  Bacteroidetes 11.37515±2.19301 14.64713±3.97861 7.62278±1.860030.515000.118500.18400
  TM70.00182±0.0012 0.18116±0.096891.89118±0.65780.066850.013070.00685
  Chloroflexi 0.00043±0.000430±0 0.00058±0.000581.000001.000001.00000
  Cyanobacteria 0.00095±0.00095 0.08708±0.06498 0.06448±0.021190.201770.741140.00562
  Deferribacteres0±0 0.00314±0.00194 0.00756±0.006830.021020.570290.25377
  Deinococcus-Thermus 0.00137±0.00095 0.00085±0.00085 0.00065±0.000651.000001.000001.00000
  Elusimicrobia0±0 0.00207±0.00089 0.00232±0.001140.055211.000000.06384
  Firmicutes 34.07855±3.97821 79.44588±4.13566 79.69249±2.765750.000000.894140.00000
  Fusobacteria 40.28194±4.39043 0.12066±0.051270.0163±0.008830.000000.053790.00000
  Gemmatimonadetes 0.00095±0.000950±0 0.00058±0.000580.528421.000001.00000
  Lentisphaerae0±0 0.00968±0.00386 0.00389±0.002510.016690.222710.00408
  Nitrospirae0±0 0.00072±0.000720±00.380790.480161.00000
  Planctomycetes 0.00044±0.00044 0.00157±0.000970±00.561990.230561.00000
  Proteobacteria 11.05874±1.14416 2.45033±0.51587 2.29854±0.573570.000000.818210.00000
  Spirochaetes0.0013±0.0013 0.89612±0.16617 0.20734±0.119010.000150.002860.07762
  Tenericutes0.013±0.01151 0.12251±0.08587 0.88127±0.365570.228920.051430.02031
  Verrucomicrobia 3.14836±1.01832 0.00072±0.00072 0.00646±0.004240.004690.197070.00492
  Acetanaerobacterium 0.00595±0.004730±00±00.225691.000000.22139
  Acetobacteraceae_uncultured0±00±0 0.00065±0.000651.000001.000000.39968
  Acholeplasma0±00±0 0.00117±0.001171.000000.500790.15974
  Acidobacteriaceae_uncultured0±00±0 0.00075±0.000751.000001.000000.39968
  Acidothermus0±0 0.00072±0.000720±00.380790.480161.00000
  Acidovorax 0.00048±0.000480±0 0.00058±0.000581.000001.000001.00000
  Acinetobacter 0.00179±0.001330±00±00.304791.000000.15540
  Actinomyces 0.00315±0.00127 0.01949±0.01252 0.00564±0.003130.211470.300680.55334
  Adlercreutzia0±0 0.00562±0.00501 0.03181±0.008250.291360.013120.00060
  Aeribacillus 0.00086±0.00086 0.00088±0.000880±01.000000.480160.52013
  Aerococcaceae_uncultured 0.00044±0.000440±00±01.000001.000001.00000
  Aerococcus0±0 0.00088±0.000880±00.380790.480161.00000
  Agrococcus 0.00043±0.000430±00±01.000001.000001.00000
  Akkermansia 3.14836±1.018320±0 0.00447±0.004470.004720.344990.00353
  Alcaligenes0±0 0.00288±0.002880±00.021020.053161.00000
  Alistipes0±0 0.00423±0.00266 0.02031±0.009150.123020.108220.03099
  Allobaculum 0.00311±0.00079 10.84206±3.941348.82073±2.94060.012520.748200.00424
  Anaerobiospirillum 0.00049±0.00049 0.00088±0.00088 0.46779±0.174071.000000.013880.00936
  Anaerofilum 2.30376±0.73263 0.05499±0.027370.0219±0.012340.004820.286110.00332
  Anaerofustis0±0 0.01313±0.011030.0104±0.003280.260650.848050.00274
  Anaerolineaceae_uncultured0±00±0 0.00058±0.000581.000001.000000.39968
  Anaerostipes 1.29186±0.40432 0.04986±0.02226 0.01231±0.011590.004840.148940.00282
  Anaerotruncus 0.77713±0.36482 1.53538±0.27758 0.81297±0.356850.109510.125600.94840
  Anaerovibrio 1.03718±0.22773 1.00465±0.37017 0.78444±0.459570.937990.773280.70861
  Anaerovorax0±0 0.01789±0.00528 0.02409±0.005720.002990.512300.00026
  Anoxybacillus 0.00183±0.00095 0.00072±0.00072 0.00239±0.001760.655740.376960.72123
  Aquabacterium 0.00044±0.000440±00.0013±0.00131.000000.500790.56788
  Arenimonas0±00±0 0.00065±0.000651.000001.000000.39968
  Bacillus 0.00438±0.002950±0 0.00129±0.000830.148620.500790.33974
  Bacteroides 11.32657±2.19329 2.86663±1.50674 0.50319±0.259370.003960.137010.00010
  Barnesiella0±00±0 0.00064±0.000641.000001.000000.39968
  Bifidobacterium0±0 0.00085±0.000850±00.380790.480161.00000
  Bilophila 0.79589±0.15162 0.00085±0.00085 0.00157±0.001060.000461.000000.00003
  Blautia 0.80417±0.24782 6.23756±1.76412 6.90259±2.627670.005090.862450.02394
  Brachybacterium0±00±0 0.00197±0.001971.000000.500790.15974
  Bradyrhizobium0±00±0 0.00065±0.000651.000001.000000.39968
  Brevundimonas 0.00216±0.001130±00±00.164131.000000.16476
  Burkholderia 0.01374±0.00306 0.00895±0.00321 0.00898±0.003960.319820.985500.42879
  Butyricicoccus0±00±0 0.00058±0.000581.000001.000000.39968
  Butyricimonas0±0 0.00602±0.00423 0.00075±0.000750.162490.233330.39968
  Candidatus_Arthromitus0±00.0005±0.0005 0.00559±0.004110.380790.231200.18080
  Candidatus_Chloracidobacterium 0.00091±0.00059 0.00135±0.000870±00.638370.230560.52013
  Candidatus_Solibacter0±00±0 0.00065±0.000651.000001.000000.39968
  Caulobacter 0.00044±0.000440±00±01.000001.000001.00000
  Cellulosilyticum 0.00048±0.000480±00±01.000001.000001.00000
  Christensenellaceae_uncultured0±00.50197±0.122 1.05035±0.299070.001390.105170.00119
  Christensenella0±0 0.00765±0.00241 0.07967±0.015970.003980.000510.00007
  Chryseobacterium 0.00136±0.000660±00±00.292631.000000.28019
  Clostridium1.0162±0.90173 0.00465±0.001910.0035±0.002880.290690.793220.27462
  Collinsella0±0 1.75193±0.70971 6.94762±2.430520.021340.053490.00609
  Comamonas 0.00588±0.00213 0.00229±0.00148 0.00369±0.001940.180180.510900.54084
  Coprococcus 0.00187±0.00101 0.34846±0.07673 0.44409±0.232770.000920.760150.06288
  Coriobacteriaceae_uncultured 0.00044±0.00044 0.07323±0.01542 0.07895±0.020650.000800.857130.00067
  Corynebacterium0±0 0.00751±0.00291 0.00305±0.001190.017170.170980.01020
  Deinococcus 0.00137±0.00095 0.00085±0.00085 0.00065±0.000651.000001.000001.00000
  Delftia 0.02537±0.00587 0.00866±0.00411 0.01068±0.002540.027830.743680.02491
  Desemzia 0.00048±0.000480±00±01.000001.000001.00000
  Desulfovibrio0.13322±0.0136 2.12679±0.44718 1.30345±0.477980.000990.221060.01686
  Diaphorobacter 0.00049±0.000490±0 0.00117±0.001171.000000.500790.56788
  Elusimicrobium0±0 0.00207±0.00089 0.00232±0.001140.055211.000000.06384
  Enhydrobacter 0.00084±0.000550±00±00.528421.000000.52013
  Enterococcus0.3229±0.065990.002±0.002 0.00649±0.003760.000750.314800.00011
  Enterorhabdus 0.00043±0.00043 0.01485±0.005790.07087±0.02060.020930.015890.00164
  Epulopiscium0.1753±0.17421 0.00088±0.000880±00.369520.480160.34371
  Erysipelothrix 0.00096±0.000960±00±00.528421.000000.52013
  Erysipelotrichaceae_Incertae_Sedis 2.50531±0.39665 0.00672±0.00292 0.01301±0.009020.000170.587040.00002
  Erysipelotrichaceae_uncultured0±0 0.00648±0.00587 0.01533±0.007850.303660.454720.05456
  Escherichia-Shigella 0.35447±0.11707 0.02743±0.009730.32604±0.15370.010920.070050.90572
  Faecalibacterium 0.00173±0.00131 0.81438±0.32885 0.00058±0.000580.021160.022560.65440
  Family_XIII_Incertae_Sedis_Incertae_Sedis0±0 0.10057±0.02552 0.20788±0.047140.001630.061290.00018
  Family_XIII_Incertae_Sedis_uncultured0±0 0.36272±0.09627 0.21403±0.052790.001930.190010.00036
  Ferruginibacter0.0008±0.00080±0 0.00058±0.000580.528421.000001.00000
  Flavobacterium 0.00096±0.00096 0.00264±0.00264 0.00058±0.000580.375840.356371.00000
  Flavonifractor 0.01386±0.01386 0.00451±0.004510.0693±0.051990.610830.225300.32534
  Flexibacter 0.00048±0.000480±00.0013±0.00131.000000.500790.56788
  Fusobacterium 40.17087±4.4684 0.03271±0.01065 0.01066±0.006780.000040.095840.00000
  GKS98_freshwater_group 0.00088±0.000880±00±00.528421.000000.52013
  Gemella 0.00776±0.00299 0.16081±0.06141 0.00508±0.001870.020780.019880.53684
  Gemmatimonadaceae_uncultured 0.00095±0.000950±00±00.528421.000000.52013
  Geobacillus 0.00087±0.000570±00±00.528421.000000.52013
  Globicatella0±00±0 0.00129±0.000831.000000.500790.15974
  Granulicatella0±0 0.00088±0.000880±00.380790.480161.00000
  Haliangium 0.00048±0.000480±00±01.000001.000001.00000
  Helicobacter 0.07094±0.02612 0.03422±0.010280.01257±0.0060.209910.085850.03429
  Herbaspirillum0±0 0.00144±0.001440±00.145000.230561.00000
  Holdemania0±0 0.06632±0.017850.09885±0.05820.002080.667660.09437
  Hydrogenoanaero bacterium0±00.0005±0.00050±00.380790.480161.00000
  Hydrogenophaga0±0 0.00072±0.00072 0.00065±0.000650.380791.000000.39968
  Iamia 0.00048±0.000480±00±01.000001.000001.00000
  Jeotgalicoccus 0.00044±0.000440±00±01.000001.000001.00000
  Klebsiella 2.78132±0.760590.0005±0.0005 0.00122±0.000790.002201.000000.00088
  Kocuria 0.00654±0.004830±00±00.190161.000000.18444
  Lachnospiraceae_Incertae_Sedis 3.56313±0.69197 1.58603±0.57302 1.85636±0.368670.039810.756050.03432
  Lachnospiraceae_uncultured 0.01129±0.00569 6.64096±2.13871 10.66917±3.44090.004690.396850.00338
  Lachnospira0±0 0.00171±0.001710.0047±0.003890.145000.455700.01020
  Lactobacillus 0.69316±0.42232 3.77028±2.08403 16.53313±5.339470.156940.038010.00458
  Lactococcus0.0058±0.00206 0.00072±0.000720±00.029000.480160.00690
  Leifsonia0±00±0 0.00065±0.000651.000001.000000.39968
  Leptolyngbya0±00±0 0.00254±0.001941.000000.126180.02552
  Leptothrix 0.00043±0.000430±00±01.000001.000001.00000
  Leucobacter 0.00044±0.00044 0.00088±0.000880±01.000000.480161.00000
  Leuconostoc 0.00314±0.001030±00±00.049281.000000.04686
  Luteimonas0±00±0 0.00099±0.000991.000001.000000.39968
  Lysobacter0±00±0 0.00058±0.000581.000001.000000.39968
  Marmoricola 0.00048±0.000480±00±01.000001.000001.00000
  Marvinbryantia0±0 0.15705±0.04201 0.13174±0.032370.002030.708280.00033
  Megamonas0±00±0 0.00058±0.000581.000001.000000.39968
  Methylobacillus0±00±0 0.00065±0.000651.000001.000000.39968
  Methylobacterium 0.00084±0.000550±0 0.00117±0.001170.528420.500790.65412
  Microbacterium0±0 0.00176±0.001760±00.145000.230561.00000
  Mogibacterium0±0 0.10606±0.02317 0.06192±0.032520.000900.285000.06173
  Morganella 0.63669±0.10501 0.00122±0.000770±00.000240.230560.00002
  Mucispirillum0±0 0.00314±0.00194 0.00756±0.006830.021020.614660.28153
  Mycobacterium 0.00088±0.000580±00±00.528421.000000.52013
  Mycoplasma0.013±0.011510±0 0.00075±0.000750.286511.000000.30851
  Nesterenkonia0±00±0 0.00064±0.000641.000001.000000.39968
  Nitrospiraceae_uncultured0±0 0.00072±0.000720±00.380790.480161.00000
  Ochrobactrum 0.01515±0.00334 0.00684±0.00496 0.00507±0.002170.177800.795730.01367
  Odoribacter 0.02862±0.011890.0005±0.0005 0.00304±0.001110.026450.376960.03689
  Opitutus0±0 0.00072±0.00072 0.00198±0.000940.380790.626180.06384
  Oscillibacter 0.00134±0.000921.91854±0.4873 0.47583±0.159360.001690.010630.00438
  Oscillospira 0.00043±0.000430.1396±0.061820.05487±0.05420.034710.328380.34728
  Ottowia0±00±0 0.00409±0.004091.000000.344990.35432
  Oxalobacter0±0 0.04147±0.014430±00.009110.009151.00000
  Paenisporosarcina0±00±0 0.00233±0.002331.000000.126180.02552
  Papillibacter0±0 0.00885±0.00248 0.01761±0.005230.002350.144540.00181
  Parabacteroides 0.00087±0.00057 0.29747±0.10585 0.76933±0.240520.010720.088780.00256
  Pasteurella0.0104±0.00628 0.00144±0.00144 0.00442±0.003270.176270.490730.49161
  Paucimonas0±0 0.00072±0.000720±00.380790.480161.00000
  Pelomonas 0.00266±0.001140±0 0.00058±0.000580.089161.000000.25499
  Peptococcaceae_uncultured0±0 0.11683±0.04023 0.05492±0.016070.008630.168940.00164
  Peptococcus0±0 0.01105±0.00382 0.01071±0.006540.008790.960400.10656
  Peptostreptococc aceae_Incertae_Sedis 9.05387±0.70459 0.05952±0.03087 0.11667±0.033460.000000.221730.00000
  Peptostreptococcus 0.00048±0.000480±00±01.000001.000001.00000
  Phascolarcto bacterium 4.99382±0.69833 3.28502±1.543390.532±0.403970.363420.099380.00003
  Phyllobacterium 0.00188±0.001010±00±00.304791.000000.15540
  Pir4_lineage 0.00044±0.000440±00±01.000001.000001.00000
  Prevotellaceae_uncultured0±0 0.64183±0.169690.9912±0.417290.001900.522340.02007
  Prevotella 0.00545±0.00269 1.28652±0.754180.93156±0.24990.102790.727720.00083
  Propionibacterium 0.00362±0.001570.004±0.00177 0.00122±0.000790.894850.168400.17603
  Proteiniphilum0±00±0 0.00467±0.004671.000000.344990.35432
  Proteus 0.03882±0.006370±00±00.000211.000000.00002
  Pseudomonas0±00±0 0.00376±0.003761.000000.063480.01020
  Pseudoxanthomonas 0.00048±0.000480.002±0.0020±00.073100.053161.00000
  RC9_gut_group0±00.2138±0.0391 0.25933±0.083930.000370.698260.00352
  Ramlibacter0±0 0.00216±0.002160±00.055210.110701.00000
  Rhodobacteraceae_uncultured 0.00044±0.000440±00±01.000001.000001.00000
  Rhodococcus 0.00048±0.000480±0 0.00058±0.000581.000001.000001.00000
  Rhodocytophaga 0.00086±0.000860±00±00.528421.000000.52013
  Rikenella0±00±0 0.00175±0.001751.000000.251180.06384
  Robinsoniella 1.60965±0.60768 0.00171±0.00171 0.00075±0.000750.014640.610740.01013
  Roseburia 0.00043±0.00043 3.29178±0.50767 0.72816±0.247790.000150.000450.00493
  Rothia 0.00083±0.00055 0.02233±0.00892 0.01708±0.007470.024180.725300.03511
  Ruminococcaceae_Incertae_Sedis 0.53333±0.180711.4356±0.21452 0.98897±0.176470.003790.124100.07627
  Ruminococcaceae_uncultured1.58302±0.3162 13.47235±2.72614 8.78594±2.202270.001040.196710.00236
  Ruminococcus0±0 0.40738±0.066010.70982±0.14780.000190.078700.00011
  Saccharopolyspora 0.00048±0.000480±00±01.000001.000001.00000
  Salinicoccus0±00±0 0.00064±0.000641.000001.000000.39968
  Saprospiraceae_uncultured0±0 0.00144±0.001440±00.145000.230561.00000
  Selenomonas0±0 0.01814±0.01216 0.01602±0.004270.147330.889510.00082
  Sinobacteraceae_uncultured0±0 0.00072±0.00072 0.00075±0.000750.380791.000000.39968
  Sphingobacteriaceae_uncultured0±00±0 0.00058±0.000581.000001.000000.39968
  Sphingobium 0.00043±0.000430±00±01.000001.000001.00000
  Sphingomonas 0.00253±0.00159 0.00232±0.001490±01.000000.110700.08762
  Sphingopyxis 0.00049±0.000490±00±01.000001.000001.00000
  Staphylococcus0.00695±0.0036 0.01002±0.005180.0181±0.006540.698690.416350.13924
  Stenotrophomonas 0.00402±0.00308 0.00144±0.00144 0.00637±0.004390.533730.305160.73974
  Streptococcus 0.34317±0.15446 0.85093±0.48484 0.13616±0.059950.375400.160710.22702
  Streptomyces0±0 0.00088±0.000880±00.380790.480161.00000
  Sutterella0.0004±0.0004 0.04729±0.01319 0.00962±0.002780.002540.011090.00213
  Syntrophobacter aceae_uncultured0.0008±0.00080±00±00.528421.000000.52013
  Tetragenococcus0±00±0 0.00186±0.001311.000000.251180.06384
  Thalassospira 0.00048±0.00048 0.01421±0.00381 0.02303±0.007680.002330.329260.00499
  Thauera0±00.0005±0.0005 0.00175±0.001750.380790.626180.06384
  Thiobacillus0±00±0 0.00759±0.007591.000000.344990.35432
  Thiotrichaceae_uncultured0±00±0 0.00075±0.000751.000001.000000.39968
  Treponema0.0013±0.0013 0.89427±0.16598 0.20351±0.118780.000440.003270.09380
  Trichococcus0±0 0.00085±0.000850±00.380790.480161.00000
  Turicibacter 0.02804±0.01479 0.00144±0.001440.00824±0.00250.088610.029230.20080
  Veillonella 0.00347±0.001280.00594±0.0033 0.00065±0.000650.578520.130880.05251
  Victivallis0±00.0088±0.00401 0.00389±0.002510.040430.325130.00408
  Xanthobacteraceae_uncultured0±00±0 0.00065±0.000651.000001.000000.39968
  Xylanibacter0±00.22435±0.186 0.01461±0.004580.254610.275390.00258
  vadinBC27_waste water-sludge_group0±00±0 0.00075±0.000751.000001.000000.39968

[i] Difference in the relative abundance of phylotypes defined at 97%-ID in rats in the Ctl, HF and HB groups. Ctl, normal diet; HF, HFD; HB, HFD supplemented with berberine for 6 weeks; HFD, high-fat diet.

Weighted UniFrac PCoA was performed to provide an overview of the gut microbiota composition. The gut microbiota composition changed significantly in response to HFD and berberine administration (Fig. 9B). PCo 1 (accounting for 77.68% of total variance) mainly reflected the effects of berberine on gut microbiota composition, as PCo 1 separated the HB group from the HF and Ctl groups. PCo 2 (accounting for 9.8% of total variance) mainly reflected the effect of different diets, as PCo 2 separated the Ctl group from the HB and HF groups. These results suggested that berberine can shift the composition of the gut microbiome of HFD-fed rats towards that of control rats. Similar results were obtained from the PCA (Fig. 9C).

Specific genera of gut bacteria responded to treatment with berberine

RDA was used to identify specific bacterial genera whose abundance was affected by HFD or berberine supplementation. Results indicated that a HFD caused a slight change in the composition of gut microbiota (Fig. 9D), whereas berberine treatment led to a significant change in the gut microbiota composition (Fig. 9E), which was proven by the Monte Carlo permutation tests (MCPP; P=0.002). Following treatment with berberine, the composition of the gut microbiome changed along the first ordination axis, which accounted for 72.8% of total variance (Fig. 9F).

Berberine appeared to significantly alter the abundance of 34 genera, 14 of which were increased, whereas the remaining 20 were decreased or eliminated (Table IV). Notably, the genus Akkermansia of the Verrucomicrobia phylum could not be detected in the HF group however, it was detected in the HB group. The genera Collinsella, Prevotellaceae_uncultured, Christensenellaceae_uncultured and Ruminococcus were detected in the HF group however, not in the HB group. Furthermore, the relative abundance of 21 genera appeared significantly increased in the HF group compared with in the control group. Among these, treatment with berberine significantly decreased the abundance of 11 genera, including Roseburia, Allobaculum, Oscillibacter, Faecalibacterium, Prevotella and Desulfovibrio. A total of 3 genera (Coprococcus, Collinsella and Blautia) remained unaffected by the HFD, however, they were significantly decreased following berberine supplementation. In addition, 10 genera appeared significantly decreased in the HFD-fed group, of which 4 were significantly increased following treatment with berberine, including Erysipelotrichaceae_Incertae_Sedis, Peptostreptococcaceae_Incertae_Sedis and Escherichia-Shigella. Furthermore, the genera Fusobacterium, Anaerostipes, Bacteroides and Phascolarctobacterium were also significantly increased by treatment with berberine.

Table IV.

Differences of the 34 genera identified by RDA between HB and HF groups.

Table IV.

Differences of the 34 genera identified by RDA between HB and HF groups.

GenusGenus for shortPhylumClassOrderFamilyHB (%)HF (%)Change (%)
AkkermansiaAkke_man Verrucomicrobia Verrucomicrobiae Verrucomicrobiales Verrucomicrobiaceae 3.14836±1.01832 0.00000±0.00000HBa
AnaerofilumAnae_filFirmicutesClostridiaClostridiales Ruminococcaceae 2.30376±0.73263 0.05499±0.027374089.2
AnaerostipesAnae_stiFirmicutesClostridiaClostridiales Lachnospiraceae 1.29186±0.40432 0.04986±0.022262490.8
BacteroidesBact_oidBacteroidetesBacteroidiaBacteroidalesBacteroidaceae 11.32657±2.19329 2.86663±1.50674295.1
BilophilaBilo_phiProteobacteria Deltaproteobacteria Desulfovibrionales Desulfovibrionaceae 0.79589±0.15162 0.00085±0.0008593122.1
Erysipelotrichaceae_Incertae_SedisErys_SedFirmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae 2.50531±0.39665 0.00672±0.0029237190.7
Escherichia-ShigellaEsch_ShiProteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae 0.35447±0.11707 0.02743±0.009731192.4
FusobacteriumFuso_bacFusobacteriaFusobacteria Fusobacteriales Fusobacteriaceae 40.17087±4.46840 0.03271±0.01065122701.9
KlebsiellaKleb_sieProteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae 2.78132±0.76059 0.00050±0.00050555400.0
Lachnospiraceae_Incertae_SedisLach_SedFirmicutesClostridiaClostridiales Lachnospiraceae 3.56313±0.69197 1.58603±0.57302124.7
MorganellaMorg_nelProteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae 0.63669±0.10501 0.00122±0.0007752081.4
Peptostreptococcaceae_Incertae_SedisPept_SedFirmicutesClostridiaClostridiales Peptostreptococcaceae 9.05387±0.70459 0.05952±0.0308715110.5
PhascolarctobacteriumPhas_bacFirmicutesClostridiaClostridiales Veillonellaceae 4.99382±0.69833 3.28502±1.5433952.0
RobinsoniellaRobi_sonFirmicutesClostridiaClostridiales Lachnospiraceae 1.60965±0.60768 0.00171±0.0017194285.6
AllobaculumAllo_bacFirmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae 0.00311±0.00079 10.84206±3.94134−100.0
AnaerotruncusAnae_truFirmicutesClostridiaClostridiales Ruminococcaceae 0.77713±0.36482 1.53538±0.27758−49.4
BlautiaBlautiaFirmicutesClostridiaClostridiales Lachnospiraceae 0.80417±0.24782 6.23756±1.76412−87.1
Christensenellaceae_unculturedChri_uncFirmicutesClostridiaClostridiales Christensenellaceae 0.00000±0.00000 0.50197±0.12200HFb
CollinsellaColl_selActinobacteriaActinobacteria Coriobacteriales Coriobacteriaceae 0.00000±0.00000 1.75193±0.70971HFb
CoprococcusCopr_cocFirmicutesClostridiaClostridiales Lachnospiraceae 0.00187±0.00101 0.34846±0.07673−99.5
DesulfovibrioDesu_vibProteobacteria Deltaproteobacteria Desulfovibrionales Desulfovibrionaceae 0.13322±0.01360 2.12679±0.44718−93.7
FaecalibacteriumFaec_bacFirmicutesClostridiaClostridiales Ruminococcaceae 0.00173±0.00131 0.81438±0.32885−99.8
Lachnospiraceae_unculturedLach_uncFirmicutesClostridiaClostridiales Lachnospiraceae 0.01129±0.00569 6.64096±2.13871−99.8
LactobacillusLact_bacFirmicutesBacilli Lactobacillales Lactobacillaceae 0.69316±0.42232 3.77028±2.08403−81.6
OscillibacterOsci_bacFirmicutesClostridiaClostridiales Ruminococcaceae 0.00134±0.00092 1.91854±0.48730−99.9
ParabacteroidesPara_bacBacteroidetesBacteroidiaBacteroidales Porphyromonadaceae 0.00087±0.00057 0.29747±0.10585−99.7
PrevotellaPrev_telBacteroidetesBacteroidiaBacteroidalesPrevotellaceae 0.00545±0.00269 1.28652±0.75418−99.6
Prevotellaceae_unculturedPrev_uncBacteroidetesBacteroidiaBacteroidalesPrevotellaceae 0.00000±0.00000 0.64183±0.16969HFb
RoseburiaRose_burFirmicutesClostridiaClostridiales Lachnospiraceae 0.00043±0.00043 3.29178±0.50767−100.0
Ruminococcaceae_Incertae_SedisRumi_SedFirmicutesClostridiaClostridiales Ruminococcaceae 0.53333±0.18071 1.43560±0.21452−62.8
Ruminococcaceae_unculturedRumi_uncFirmicutesClostridiaClostridiales Ruminococcaceae 1.58302±0.31620 13.47235±2.72614−88.2
RuminococcusRumi_cocFirmicutesClostridiaClostridiales Ruminococcaceae 0.00000±0.00000 0.40738±0.06601HFb
StreptococcusStre_cocFirmicutesBacilli Lactobacillales Streptococcaceae 0.34317±0.15446 0.85093±0.48484−59.7
TreponemaTrep_nemSpirochaetes Spirochaetes(class)Spirochaetales Spirochaetaceae 0.00130±0.00130 0.89427±0.16598−99.9

{ label (or @symbol) needed for fn[@id='tfn5-mmr-15-05-2765'] } Data are expressed as the mean ± standard deviation. Only the percentage change values with significant differences (P<0.05) between the HB and HF groups are indicated. Those that were not significant are indicated as follows:

a HB, found only in berberine-treated rats

b HF, found only in the HFD-fed rats. HF, HFD; HB, HFD supplemented with berberine for 6 weeks; HFD, high-fat diet.

In order to identify the specific genera of intestinal bacteria that could be associated with the beneficial effects of berberine, Spearman's correlation analysis was performed between the 34 genera whose distribution appeared to be altered following berberine supplementation and a number of physiological parameters. The analyses revealed that weight, glucose intolerance, FITC-dextran area and L-cell number were correlated with the abundance of several genera (Table V).

Table V.

Spearman's correlation between the specific genera altered by berberine administration according to redundancy analysis and host metabolic parameters.

Table V.

Spearman's correlation between the specific genera altered by berberine administration according to redundancy analysis and host metabolic parameters.

Body weightFBGFINSHOMA-IRAUC of OGTTFITC-dextran areaclaudin-1claudin-2ZO-1occludinL-cellsGLP-1GLP-2GIPPPPYY

[i] Values are Spearman correlation coefficients. Only significant correlations (P<0.05) are indicated. ns, not significant (P>0.05); FBG, fasting blood glucose; FINS, fasting blood insulin; HOMA-IR, homeostatic model assessment of insulin resistance; AUC, area under curve; OGTT, oral glucose tolerance test; FITC, fluorescein isothiocyanate; ZO-1, zonula occludens-1; GLP, glucagon-like peptide; GIP, gastric inhibitory polypeptide; PP, pancreatic polypeptide; PYY, peptide YY.


It has previously been demonstrated that berberine participates in the regulation of glucose and lipid metabolism through targeting gut microbiota; however, the implication of its modulatory effects on gut microbiota in metabolic disorders has not yet been examined. Growing evidence has suggested that the gut microbiome contributes to the systemic low-grade inflammation that is characteristic of metabolic disorders. LPS from intestinal bacteria can leak into the circulation through the damaged intestinal mucosa (15), where it can cause metabolic endotoxemia and the production of proinflammatory cytokines, thereby contributing to insulin resistance and related metabolic disorders (26,27). Plasma LPS levels are a direct biomarker of systemic inflammation. The present study revealed that berberine can significantly decrease plasma LPS levels, which is in accordance with previous results reporting that berberine can significantly prevent HFD-induced systemic inflammation by decreasing serum LPS-binding protein levels (14). Since macrophage infiltration and oxidative stress in adipose tissue participate in inflammation and insulin resistance (2830), a number of inflammatory and oxidative stress factors were investigated in order to evaluate the role of berberine in systemic inflammation. Berberine appeared to reduce the HFD-induced mRNA expression levels of markers of inflammation (IL-1β and PAI-1), oxidative stress (NADPHox and STAMP-2) and macrophage infiltration (MCP-1 and F4/80) in visceral adipose tissue. Berberine has previously been reported to downregulate the expression of the proinflammatory cytokines TNF-α, IL-1, IL-6 and MCP-1 in white adipose tissue from db/db mice (31). Furthermore, the correlations that were revealed in the present study between these markers and plasma LPS levels further support the hypothesis that berberine can improve the endotoxemia-induced systemic inflammation in HFD-fed rats.

The present results suggested that the beneficial effect of berberine on endotoxemia is unlikely to be a result of a decrease in Gram-negative bacteria (Table III), thus indicating that berberine may reduce endotoxemia through reducing intestinal permeability. Alterations in intestinal permeability have previously been associated with alterations in the expression, localization and distribution of tight junction proteins, including claudins, ZO-1 and occludin (32). It has also been suggested that berberine may directly affect the expression of tight junction proteins. Amasheh et al (33) reported that in HT-29/B6 cells, berberine increased the mRNA expression levels of claudin-1, however, not claudin-2. In a rat model of LPS-induced injury, berberine administration following LPS injection did not appear to ameliorate the expression and distribution of the tight junction proteins claudin-1, claudin-4, ZO-1 and occludin, and had no effect on intestinal permeability. However, pretreatment with berberine for 7 days was reported to partially attenuate the LPS-induced destruction and redistribution of tight junction proteins (34). Considering the pharmacokinetic features of berberine, it may be hypothesized that berberine required a longer time-frame to reach its effective concentration. The present study demonstrated that berberine supplementation for 6 weeks significantly increased the expression of claudin-1 and ZO-1 in the proximal colon of HFD-induced obese rats. In addition, berberine appeared to partially restore the intestinal distribution of claudin-1 and claudin-2. These results suggested that berberine, through increasing the expression and restoring the distribution of tight junction proteins may contribute to the restoration of intestinal epithelial integrity.

In addition to its direct effects on the expression of tight junction proteins, berberine has been reported to indirectly restore gut permeability, through modulating gut microbiota. Previous studies have suggested that gut microbiota may regulate epithelial permeability (32,35,36). SCFAs, which are the main metabolic products of bacterial fermentation, have been suggested to improve the function of the gut barrier by promoting epithelial cell growth and facilitating tight junction formation (37,38). Zhang et al (14) reported that berberine, through increasing the SCFA-producing genera Blautia and Allobaculum, enhanced intestinal integrity and thus antagonized obesity. However, the results of the present study revealed that berberine significantly decreased Blautia and Allobaculum bacteria, although intestinal permeability was improved. The present results agree with a previous report by Xie et al (2) demonstrating that berberine exerted anti-obesity effects partly by decreasing the degradation of dietary polysaccharides and fecal SCFA production to inhibit energy harvest. Previous studies have suggested that the relationship between fecal SCFAs and the regulation of host metabolism is important and complex (2,16). In contrast to the model used by Zhang et al (14), the present study evaluated the effect of berberine in rats maintained on a HFD for 14 weeks, resembling the clinical situation. However, future studies are required to investigate the role of berberine on SCFA-producing genera of intestinal bacteria.

In the present study, a Spearman's correlation analysis revealed a negative correlation between intestinal permeability and the abundance of the Phascolarctobacterium and Collinsella genera, and berberine supplementation significantly increased the abundance of the genus Phascolarctobacterium. Intestinal permeability appeared positively correlated with the abundance of the Anaerotruncus and Oscillibacter genera (Table V). The present findings indicated that Phascolarctobacterium, Anaerotruncus and Oscillibacter may be solely responsible for the beneficial effects of berberine on intestinal permeability. A significant 10-fold decrease in the genus Oscillibacter was observed in berberine-treated HFD-fed rats. It has previously been reported that a HFD significantly increased the abundance of Oscillibacter, which was negatively correlated with transepithelial resistance and ZO-1 mRNA expression levels in the proximal colon (39). In accordance with the previous study, the present results suggested that berberine may increase ZO-1 mRNA expression levels and intestinal permeability, possibly by inhibiting Oscillibacter abundance. In addition, the genus Akkermansia was reported to be present exclusively in berberine-treated rats. Previous studies have suggested that Akkermansia muciniphila may restore the thickness of the intestinal mucosa and counteract HFD-induced mucosal barrier dysfunction in the colon (40), whereas it has been suggested that this species may hold a key role in gut barrier function and metabolic inflammation (41). However, a significant correlation between the genus Akkermansia and intestinal permeability was not observed in the present study. Further work is required to explore the putative relationship between the abundance of Akkermansia bacteria and the integrity of the gut barrier.

The modulation of gut hormone levels by berberine has been reported to serve an important role in improving energy homeostasis. Previous studies have revealed that berberine increased the number of L-cells and the mRNA expression levels of proglucagon in the ileum, whereas it promoted GLP-1 secretion in normal and diabetic rats (9,10). In the present study, berberine significantly increased the portal plasma levels of GLP-1 and GLP-2, whereas it also increased the number of L-cells and the mRNA expression levels of proglucagon in the proximal colon. Multiple lines of evidence have linked gut microbiota with the enteroendocrine system, whereas SCFAs are the most studied among gut microbial metabolites (42). In the present study, Spearman's correlation analysis revealed that L-cell numbers were positively correlated with the abundance of 4 genera (Akkermansia, Anaerostipes, Bilophila and Oscillibacter) and negatively correlated with the abundance of the genus Lactobacillus (Table V). Previous studies reported a positive correlation between the abundance of bacteria of the Akkermansia genus and L-cell numbers in the colon, whereas Akkermansia muciniphila administration significantly increased GLP-1 release from colonic L-cells (43,44). Sequencing results of the present study revealed that the abundance of Akkermansia was significantly increased by berberine, although the correlation between Akkermansia and GLP-1 levels was not significant. Based on previous research that correlated the abundance of 10 genera with L-cell numbers (43), the present study confirmed that berberine increased the abundance of the genus Akkermansia and decreased the abundance of the genus Lactobacillus, which appeared to be associated with the increase in L-cell numbers and enteroendocrine peptide secretion from L-cells. In addition, Spearman's correlation analysis revealed plasma GIP levels to be negatively correlated with the abundance of the Robinsoniella genus.

The present study suggested that the wide shift in the gut microbiota composition induced by berberine may attenuate insulin resistance and related metabolic disorders in HFD-fed rats via several pathways. Firstly, berberine supplementation alleviated metabolic endotoxemia and subsequent systemic inflammation, via restoring the integrity of the gut barrier through increasing the expression and restoring the distribution of tight junction proteins. Furthermore, berberine modulated the plasma levels of gut hormones involved in glucose regulation and energy homeostasis, possibly via interfering with the composition of the gut microbiome. In conclusion, the present results suggested that berberine may be a potential therapeutic strategy for the treatment of obesity and insulin resistance. However, further study is required to delineate the mechanism of action of berberine.


This study was supported by the National Natural Science Foundation of China (grant no. 81170738).



Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, et al: Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 93:2559–2565. 2008. View Article : Google Scholar : PubMed/NCBI


Xie W, Gu D, Li J, Cui K and Zhang Y: Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PLoS One. 6:e245202011. View Article : Google Scholar : PubMed/NCBI


Gomes AP, Duarte FV, Nunes P, Hubbard BP, Teodoro JS, Varela AT, Jones JG, Sinclair DA, Palmeira CM and Rolo AP: Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. Biochim Biophys Acta. 1822:185–195. 2012. View Article : Google Scholar : PubMed/NCBI


Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, et al: Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 55:2256–2264. 2006. View Article : Google Scholar : PubMed/NCBI


Liu L, Yu YL, Yang JS, Li Y, Liu YW, Liang Y, Liu XD, Xie L and Wang GJ: Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol. 381:371–381. 2010. View Article : Google Scholar : PubMed/NCBI


Pan GY, Huang ZJ, Wang GJ, Fawcett JP, Liu XD, Zhao XC, Sun JG and Xie YY: The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption. Planta Med. 69:632–636. 2003. View Article : Google Scholar : PubMed/NCBI


Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, et al: Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 10:1344–1351. 2004. View Article : Google Scholar : PubMed/NCBI


Wang Y, Yi X, Ghanam K, Zhang S, Zhao T and Zhu X: Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption. Metabolism. 63:1167–1177. 2014. View Article : Google Scholar : PubMed/NCBI


Lu SS, Yu YL, Zhu HJ, Liu XD, Liu L, Liu YW, Wang P, Xie L and Wang GJ: Berberine promotes glucagon-like peptide-1 (7–36) amide secretion in streptozotocin-induced diabetic rats. J Endocrinol. 200:159–165. 2009. View Article : Google Scholar : PubMed/NCBI


Yu Y, Liu L, Wang X, Liu X, Liu X, Xie L and Wang G: Modulation of glucagon-like peptide-1 release by berberine: In vivo and in vitro studies. Biochem Pharmacol. 79:1000–1006. 2010. View Article : Google Scholar : PubMed/NCBI


Liu YT, Hao HP, Xie HG, Lai L, Wang Q, Liu CX and Wang GJ: Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos. 38:1779–1784. 2010. View Article : Google Scholar : PubMed/NCBI


Chen W, Miao YQ, Fan DJ, Yang SS, Lin X, Meng LK and Tang X: Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. AAPS PharmSciTech. 12:705–711. 2011. View Article : Google Scholar : PubMed/NCBI


Aronsson L, Huang Y, Parini P, Korach-André M, Håkansson J, Gustafsson JÅ, Pettersson S, Arulampalam V and Rafter J: Decreased fat storage by Lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). PLoS One. 5:e130872010. View Article : Google Scholar : PubMed/NCBI


Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, Li M, Zhang C, Zhang Z, Zhang Y, et al: Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One. 7:e425292012. View Article : Google Scholar : PubMed/NCBI


Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, et al: Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 58:1091–1103. 2009. View Article : Google Scholar : PubMed/NCBI


Cani PD, Lecourt E, Dewulf EM, Sohet FM, Pachikian BD, Naslain D, De Backer F, Neyrinck AM and Delzenne NM: Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr. 90:1236–1243. 2009. View Article : Google Scholar : PubMed/NCBI


Cani PD, Neyrinck AM, Maton N and Delzenne NM: Oligofructose promotes satiety in rats fed a high-fat diet: Involvement of glucagon-like peptide-1. Obes Res. 13:1000–1007. 2005. View Article : Google Scholar : PubMed/NCBI


Cani PD, Hoste S, Guiot Y and Delzenne NM: Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats. Br J Nutr. 98:32–37. 2007. View Article : Google Scholar : PubMed/NCBI


Tazoe H, Otomo Y, Karaki S, Kato I, Fukami Y, Terasaki M and Kuwahara A: Expression of short-chain fatty acid receptor GPR41 in the human colon. Biomed Res. 30:149–156. 2009. View Article : Google Scholar : PubMed/NCBI


Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F and Gribble FM: Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 61:364–371. 2012. View Article : Google Scholar : PubMed/NCBI


des Rieux A, Pourcelle V, Cani PD, Marchand-Brynaert J and Préat V: Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv Drug Deliv Rev. 65:833–844. 2013. View Article : Google Scholar : PubMed/NCBI


Psichas A, Sleeth ML, Murphy KG, Brooks L, Bewick GA, Hanyaloglu AC, Ghatei MA, Bloom SR and Frost G: The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obes (Lond). 39:424–429. 2015. View Article : Google Scholar : PubMed/NCBI


Feng Y, Li Y, Chen C, Lin X, Yang Y, Cai H, Lv Z, Cao M, Li K, Xu J, et al: Inhibiting roles of berberine in gut movement of rodents are related to activation of the endogenous opioid system. Phytother Res. 27:1564–1571. 2013.PubMed/NCBI


Shan CY, Yang JH, Kong Y, Wang XY, Zheng MY, Xu YG, Wang Y, Ren HZ, Chang BC and Chen LM: Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats. J Endocrinol. 218:255–262. 2013. View Article : Google Scholar : PubMed/NCBI


Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI


Kim KA, Gu W, Lee IA, Joh EH and Kim DH: High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS One. 7:e477132012. View Article : Google Scholar : PubMed/NCBI


Glass CK and Olefsky JM: Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15:635–645. 2012. View Article : Google Scholar : PubMed/NCBI


Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M and Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 114:1752–1761. 2004. View Article : Google Scholar : PubMed/NCBI


Shoelson SE, Lee J and Goldfine AB: Inflammation and insulin resistance. J Clin Invest. 116:1793–1801. 2006. View Article : Google Scholar : PubMed/NCBI


Shoelson SE, Herrero L and Naaz A: Obesity, inflammation and insulin resistance. Gastroenterology. 132:2169–2180. 2007. View Article : Google Scholar : PubMed/NCBI


Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, Kim WS and Kim JB: Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab. 296:E955–E964. 2009. View Article : Google Scholar : PubMed/NCBI


Everard A and Cani PD: Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol. 27:73–83. 2013. View Article : Google Scholar : PubMed/NCBI


Amasheh M, Fromm A, Krug SM, Amasheh S, Andres S, Zeitz M, Fromm M and Schulzke JD: TNFalpha-induced and berberine-antagonized tight junction barrier impairment via tyrosine kinase, Akt and NFkappaB signaling. J Cell Sci. 123:4145–4155. 2010. View Article : Google Scholar : PubMed/NCBI


Ma JY, Feng R, Tan XS, Ma C, Shou JW, Fu J, Huang M, He CY, Chen SN, Zhao ZX, et al: Excretion of berberine and its metabolites in oral administration in rats. J Pharm Sci. 102:4181–4192. 2013. View Article : Google Scholar : PubMed/NCBI


Yu LC, Wang JT, Wei SC and Ni YH: Host-microbial interactions and regulation of intestinal epithelial barrier function: From physiology to pathology. World J Gastrointest Pathophysiol. 3:27–43. 2012. View Article : Google Scholar : PubMed/NCBI


Greiner T and Bäckhed F: Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol Metab. 22:117–123. 2011. View Article : Google Scholar : PubMed/NCBI


Ichikawa H and Sakata T: Stimulation of epithelial cell proliferation of isolated distal colon of rats by continuous colonic infusion of ammonia or short-chain fatty acids is nonadditive. J Nutr. 128:843–847. 1998.PubMed/NCBI


Peng L, Li ZR, Green RS, Holzman IR and Lin J: Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 139:1619–1625. 2009. View Article : Google Scholar : PubMed/NCBI


Lam Y, Ha CW, Campbell CR, Mitchell AJ, Dinudom A, Oscarsson J, Cook DI, Hunt NH, Caterson ID, Holmes AJ, et al: Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS One. 7:e342332012. View Article : Google Scholar : PubMed/NCBI


Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, et al: Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA. 110:9066–9071. 2013. View Article : Google Scholar : PubMed/NCBI


Anhê FF, Roy D, Pilon G, Dudonné S, Matamoros S, Varin TV, Garofalo C, Moine Q, Desjardins Y, Levy E, et al: A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut. 64:872–883. 2015. View Article : Google Scholar : PubMed/NCBI


Cani PD, Everard A and Duparc T: Gut microbiota, enteroendocrine functions and metabolism. Curr Opin Pharmacol. 13:935–940. 2013. View Article : Google Scholar : PubMed/NCBI


Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Neyrinck AM, Possemiers S, Van Holle A, François P, de Vos WM, et al: Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes. 60:2775–2786. 2011. View Article : Google Scholar : PubMed/NCBI


Hansen KB, Rosenkilde MM, Knop FK, Wellner N, Diep TA, Rehfeld JF, Andersen UB, Holst JJ and Hansen HS: 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J Clin Endocrinol Metab. 96:E1409–E1417. 2011. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

May 2017
Volume 15 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
Xu, J.H., Liu, X.Z., Pan, W., & Zou, D.J. (2017). Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels. Molecular Medicine Reports, 15, 2765-2787.
Xu, J. H., Liu, X. Z., Pan, W., Zou, D. J."Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels". Molecular Medicine Reports 15.5 (2017): 2765-2787.
Xu, J. H., Liu, X. Z., Pan, W., Zou, D. J."Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels". Molecular Medicine Reports 15, no. 5 (2017): 2765-2787.